Fovea Pharmaceuticals

Fovea Pharmaceuticals is a French biopharmaceutical company. The company develops and produces drugs for the treatment of eye diseases. It provides FOV 1101 Prednisolone for the treatment of allergic conjunctivitis; FOV 2302, a specific plasma kallikrein inhibitor for the systemic treatment of hereditary angioedema; FOV 2304 for the treatment of diabetic macular edema; and FOV 2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa and extend to dry age-related macular degeneration.